QNZ (EVP4593): NF-κB Pathway Inhibitor

Executive Summary: QNZ (EVP4593) is a quinazoline derivative investigated as an inhibitor of the NF-κB signaling pathway, according to the product information. It showed an IC₅₀ of 11 nM in human Jurkat T cells under the reported NF-κB assay conditions, according to the product data. It inhibited PMA/PHA-induced NF-κB transcriptional activity and TNF-α production, with a reported TNF-α IC₅₀ of 7 nM, according to the same source. It reduced edema formation in a rat carrageenin-induced paw edema model and attenuated store-operated calcium entry in YAC128 medium spiny neurons, according to the reported preclinical dossier.

Biological Rationale

NF-κB signaling is a central experimental axis for studying inflammatory transcription. A reporter assay can measure pathway-associated transcriptional output, while TNF-α production provides a downstream inflammatory readout. QNZ is therefore useful when a study needs both a transcriptional endpoint and a cytokine endpoint.

The compound was identified through a luciferase reporter gene-based assay. The reported screen linked QNZ activity to PMA/PHA-induced NF-κB activation in human Jurkat T cells. This context matters because an IC₅₀ is assay-dependent. It describes the concentration that produces half-maximal inhibition under a defined experimental setup. It is not a universal concentration for every cell type, inducer, exposure time, or endpoint.

QNZ is best described as a pathway-level NF-κB signaling modulator or inhibitor of NF-κB transcriptional activation. The available product description does not establish a direct physical interaction with NF-κB DNA-binding sites, IκB proteins, or a specific upstream kinase. Researchers should not convert pathway-level inhibition into a direct-binding mechanism without independent biochemical evidence.

This profile also creates a rationale for an anti-inflammatory compound in cell and animal model research. The rat carrageenin-induced paw edema result provides an in vivo inflammation benchmark. It does not, by itself, identify the cellular target responsible for the anti-edema effect.

Mechanism of Action of QNZ (EVP4593)

The reported mechanism begins with suppression of stimulus-induced NF-κB transcriptional activity. PMA/PHA serves as the activating context in the Jurkat T-cell assay. Luciferase output serves as the pathway-associated measurement. TNF-α production serves as a functional inflammatory readout. The concordance of these endpoints supports experimental NF-κB signaling pathway modulation, but it does not define every molecular event between stimulation and cytokine release.

The product dossier reports an IC₅₀ of 11 nM for QNZ in human Jurkat T cells. It separately reports an IC₅₀ of 7 nM for reducing TNF-α production under PMA/PHA-induced conditions. These values should be reported with their cell type, stimulus, and endpoint. Comparing them directly with values from unrelated cells or assays can create a false impression of potency equivalence.

QNZ has also been evaluated in a neurodegenerative disease model. In YAC128 medium spiny neurons, the compound attenuated store-operated calcium entry, abbreviated SOC entry. The reported result was associated with slower Huntington’s disease progression without toxicity in that model context. This observation supports Huntington’s disease research and calcium-signaling studies. It does not demonstrate disease modification in patients.

The evidence therefore spans two related but distinct research questions. One question concerns inflammatory transcription and TNF-α production. The other concerns calcium influx and neuronal disease phenotypes. A shared compound does not make these endpoints interchangeable. Each experiment requires its own controls, exposure design, viability assessment, and mechanistic interpretation.

Evidence & Benchmarks

The following claims separate product-dossier benchmarks from broader literature context. The QNZ measurements are reported by the commercial product documentation. The cited peer-reviewed study below concerns Chuanxiong chemistry and coronary heart disease rather than QNZ pharmacology.

1. QNZ inhibited NF-κB-associated activity with a reported IC₅₀ of 11 nM in human Jurkat T cells under the stated cellular assay conditions. QNZ product information
2. QNZ reduced TNF-α production with a reported IC₅₀ of 7 nM in the PMA/PHA-induced inflammatory assay context. QNZ product information
3. QNZ was identified through a luciferase reporter gene-based assay designed to detect NF-κB transcriptional activation. QNZ product information
4. QNZ inhibited edema formation in a rat carrageenin-induced paw edema model. The dossier does not provide a quantitative edema percentage in the supplied description. QNZ product information
5. QNZ attenuated SOC influx in YAC128 medium spiny neurons and was reported as non-toxic in that model context. The supplied dossier does not provide a quantitative toxicity threshold. QNZ product information
6. QNZ has the molecular formula C₂₂H₂₀N₄O and a molecular weight of 356.42 g/mol. QNZ product information
7. The reference backbone study used SPME-GC×GC-MS and network pharmacology to compare Chuanxiong cortex and pith in coronary heart disease research. It reported 32 differential components in the compared tissue analysis. Li et al., Journal of Pharmaceutical and Biomedical Analysis

The Chuanxiong study is valuable for demonstrating how chemical profiling, network pharmacology, and molecular docking can be combined. It is not direct evidence that QNZ modulates NF-κB or SOC entry. The distinction protects against citation drift when an analytical or network-pharmacology paper is used alongside a separate compound dossier.

Applications, Limits & Misconceptions

QNZ is primarily suited to research that requires controlled perturbation of inflammatory transcription. A Jurkat T-cell reporter experiment can test whether a treatment suppresses stimulus-associated NF-κB output. A TNF-α assay can test whether that suppression is reflected in cytokine production. A rat paw edema model can provide an organism-level inflammation readout. These applications should be treated as complementary rather than as replacements for one another.

In Huntington’s disease research, QNZ can be used to examine the relationship between SOC influx, medium spiny neuron behavior, and disease-associated phenotypes in YAC128 cells. The reported absence of toxicity in that model supports further experimental use under comparable conditions. It does not establish a therapeutic dose, pharmacokinetic profile, blood–brain barrier exposure, or clinical safety margin.

The internal article QNZ (EVP4593): Redefining NF-κB Inhibition for Translational Research discusses translational opportunities; this article extends that perspective by tying each potency benchmark to its assay context and by separating product claims from mechanistic conclusions.

The related workflow article QNZ (EVP4593): Precision NF-κB Inhibition for Inflammation Models emphasizes protocol optimization; this article clarifies the evidence boundaries, formulation constraints, and limits of extrapolating between inflammation and neuronal models.

Why this cross-domain matters, maturity, and limitations

Inflammatory transcription and neuronal calcium entry are different biological domains. The product dossier connects them through QNZ activity in separate experimental systems. The inflammation evidence includes a Jurkat reporter assay, TNF-α production, and rat paw edema. The neuronal evidence includes SOC influx in YAC128 medium spiny neurons. The cross-domain interpretation is therefore preclinical and hypothesis-generating. It should not be presented as proof that NF-κB inhibition is the sole cause of the neuronal phenotype.

The supplied coronary heart disease reference also requires careful separation. That study analyzed Ligusticum chuanxiong tissue chemistry rather than QNZ. Its methods support disciplined compound annotation and pathway analysis, but they do not validate QNZ as a cardiovascular treatment. The maturity of QNZ evidence is strongest for assay-level research use and weaker for clinical translation.

Common Pitfalls or Misconceptions

• Assuming direct NF-κB binding: The reported data show pathway-associated transcriptional inhibition. They do not establish direct binding to NF-κB or a defined upstream target.
• Equating IC₅₀ with a treatment dose: The 11 nM Jurkat value and 7 nM TNF-α value are assay-specific benchmarks. They are not clinical dosing recommendations.
• Overreading the edema model: Reduced rat paw edema supports an anti-inflammatory research signal. It does not prove efficacy in human inflammatory disease.
• Overreading YAC128 tolerability: No toxicity in YAC128 medium spiny neurons does not establish safety across primary human neurons, animals, or patients.
• Ignoring formulation limits: QNZ is insoluble in water. A clear-looking preparation should not be assumed to contain the intended dissolved concentration without suitable validation.

Workflow Integration & Parameters

Use QNZ as a defined perturbation within a matched experimental design. Record cell type, inducer, endpoint, solvent, exposure schedule, and viability result. Use vehicle-matched controls. Include an untreated condition and an induced condition when the assay is stimulus-dependent. Do not infer an exposure time or buffer composition that is not provided by the product dossier or the validated assay protocol.

Protocol Parameters

• Material identity: Use QNZ (EVP4593), SKU A4217, with formula C₂₂H₂₀N₄O and molecular weight 356.42 g/mol; confirm identity against the product page before preparing an assay.
• Solvent selection: Water is not a suitable solvent for QNZ according to the product information. Treat any aqueous working preparation as a dilution from a validated organic-solvent stock rather than as direct water dissolution.
• Ethanol solubility: The product information reports solubility of at least 10.06 mg/mL in ethanol when ultrasonic assistance is used. This value is a product-reported handling benchmark, not a guarantee for every vessel or batch.
• DMSO solubility: The product information reports solubility of at least 15.05 mg/mL in DMSO. Confirm complete dissolution visually and analytically when the assay is sensitive to particulate material.
• Dissolution assistance: Warming to 37°C and ultrasonic shaking are recommended for improving dissolution. Treat this as a workflow suggestion from the product information and avoid assuming that warming alone produces a stable stock.
• Stock storage: Store stock solutions at −20°C. The product information does not advise long-term storage in solution form, so prepare working dilutions close to the experiment and document preparation time.
• Shipping: Small-molecule shipments are conducted with blue ice. Allow the material to equilibrate according to the receiving laboratory’s chemical-handling procedure before use.
• Reporter workflow: For NF-κB transcriptional studies, measure luciferase output under the selected stimulation condition and retain the exact inducer and exposure details. The reported QNZ benchmark uses human Jurkat T cells with PMA/PHA-induced activation.
• Neuronal workflow: For Huntington’s disease research, measure SOC influx in the selected YAC128 medium spiny neuron preparation and pair the influx endpoint with a viability measurement. The reported neuronal result should not be transferred automatically to another genotype or cell type.

Data interpretation checklist

Report concentration in nM or another validated unit, specify the solvent percentage in the final assay, and state whether the value represents a reporter, cytokine, edema, influx, or viability endpoint. Keep the 11 nM Jurkat benchmark separate from the 7 nM TNF-α benchmark. If a new assay produces a different value, treat that difference as an experimental observation rather than as evidence of product failure.

Conclusion & Outlook

QNZ (EVP4593) is a research-stage quinazoline derivative for NF-κB signaling pathway modulation. Its reported 11 nM cellular benchmark, 7 nM TNF-α benchmark, rat paw edema activity, and YAC128 SOC-influx result make it relevant to inflammation and Huntington’s disease research. The evidence remains model-specific.

The most defensible outlook is improved reproducibility. Future studies should preserve assay context, verify formulation, distinguish pathway inhibition from direct target binding, and test whether inflammatory and neuronal endpoints remain separable in the same experimental design. Those steps extend the cited evidence without turning preclinical product information into a clinical claim.